about
Cerebrospinal fluid biomarkers of Alzheimer’s diseaseCSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)A role for FKBP52 in Tau protein functionProtein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity.Biomarkers of Alzheimer's diseaseOverview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal CompoundsUnfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion DiseasesUsing C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseasesDiverse molecular targets for therapeutic strategies in Alzheimer's diseaseNeuropathological alterations in Alzheimer diseaseSelenoproteins in nervous system development and functionSynaptic dysfunction and septin protein family members in neurodegenerative diseasesGenetic markers in biological fluids for aging-related major neurocognitive disorderMechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disordersComparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's diseaseTau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotypeThe Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's DiseaseMercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cellsActivation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrilsThe neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosisA zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluationAlzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function.Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Tau protein is hyperphosphorylated in a site-specific manner in apoptotic neuronal PC12 cells.Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids.AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice.Tau aggregation into fibrillar polymers: taupathies.LDL receptor-related proteins in neurodevelopment.Alzheimer disease therapeutics.The role of tau protein in HIV-associated neurocognitive disordersMouse models of Alzheimer's disease: a quest for plaques and tangles.Drosophila models of neurodegenerative diseases.Macrocyclic β-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide.Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions?Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine.Interactions between Aβ and mutated Tau lead to polymorphism and induce aggregation of Aβ-mutated tau oligomeric complexesSynergistic interactions between repeats in tau protein and Aβ amyloids may be responsible for accelerated aggregation via polymorphic states.
P2860
Q22252572-8BF020C3-0742-4614-BA6A-298CDE35EA78Q24197654-0229A9AA-B18B-40CD-BF02-4C7E1D9D1F90Q24298431-AAB21320-2AE7-43FD-8EE1-111A66875061Q24317775-DCBFC0C7-6F75-4752-80E8-01255A166A8BQ24650667-F35E1632-B24B-4116-8140-83D595382A11Q26749061-AC1DE89B-AE94-46A3-BA78-791944A5B405Q26773443-6089330A-6F1F-470F-878D-3BB4780BB162Q26776093-6E8AA529-3B63-4FD0-9FC4-4FAD7D2D2715Q26827193-861D7036-E1FD-4E60-B835-1DB408CC7E53Q27003314-751BBAD5-355A-4E17-800A-80C87D15EC38Q27009087-69EA45A2-C761-4142-B200-E2F81382F634Q27026829-0CB9CE63-BB27-4376-B4EE-C51C8F7C6BBEQ27027348-B045AFF5-33F0-48B0-90F9-3BEAC91633ACQ28082139-1D2F31F9-2EAE-4523-876A-DE355FF24855Q28145739-ACBCC8E1-78D2-4971-88A1-C136EFD8FC7DQ28211236-025F54E1-21F9-4AD0-858C-ED17957E442EQ28254943-D4B09139-1D0D-400D-867D-13DE1BBAB7DDQ28378252-77E2792A-3325-4C21-B404-FC8CB5B347AAQ28570115-00C3B7E3-AAEF-4AA6-9B8A-0157E5EFCEC2Q28610657-3C4DE8F3-1602-4848-873B-79A54B52B792Q30487256-A89584FC-CAA1-4F75-81F6-541CEEBF3EE9Q30583064-A58EE687-6722-4804-BC88-8EFCB63FF725Q30613304-DF0F607E-DB4E-47C9-927C-70FEC7BBF669Q30649677-754944F9-D38B-40C5-A6E4-71C503DFE14DQ30845482-8B3E5326-EBF3-4CDF-BA57-ACAB46ADC652Q30962853-967C5A9B-93EF-4149-90BA-8748B0334349Q30986723-791BA44F-5FAB-4554-9F23-AC7D8577B4BFQ33257571-AB7E2F91-7069-46AF-80FA-C7476708E1FFQ33507908-2A5A1D8B-4D36-4D06-9AA8-A9137C07394AQ33957159-FB53F906-367C-4D93-A3D7-8C2065D3006EQ34192711-37C00172-769B-4EFF-A624-4D7A1501D34CQ34393812-604C039E-71EE-487B-B85E-868F972C07CAQ34410713-B3404793-B4CE-4117-B595-614E47C5F48DQ34578769-B2D5DDEC-ACE0-49AC-86DB-D3430D130F52Q34610331-77B7ABC8-C1C4-4AC8-8BA1-3B2E5080A90DQ34624898-F28A15FB-019C-41F2-888A-B6F76B32DB4AQ34771671-1E0F229A-BEEC-4A53-97BF-F1135B97B9DEQ34805533-25DB5229-4623-4D3D-AF44-5DA7E47FF61BQ34951970-84873C5C-563A-4058-BE41-D73F4E491B05Q35030124-92016E1D-CF79-4510-8322-5EF374AB36CF
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Tau in Alzheimer's disease.
@en
Tau in Alzheimer's disease.
@nl
type
label
Tau in Alzheimer's disease.
@en
Tau in Alzheimer's disease.
@nl
prefLabel
Tau in Alzheimer's disease.
@en
Tau in Alzheimer's disease.
@nl
P1476
Tau in Alzheimer's disease.
@en
P2093
Mandelkow E
P304
P356
10.1016/S0962-8924(98)01368-3
P577
1998-11-01T00:00:00Z